Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii.

Translated title of the contribution: Role of lymphadenectomy in the treatment of Merkel-cell tumors in i and ii stages

M. T. Lonardo, U. Marone, M. G. Chiofalo, R. Cerra, S. Mori, C. Caracò, C. Misso, A. Germano, L. Pezzullo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Merkel cell carcinoma (MCC) is a rare, malignant skin cancer, exhibiting neuroendocrine differentiation, with a significant incidence of locoregional lymph nodal involvement (40%-73%). The accepted staging system classifies MCC as: stage I, localized skin disease; stage II, regional lymph node disease; stage III, metastatic disease. The clinical differentiation of stage I and II patients is difficult and understaging is frequent. Surgery, as first approach, represents the leading treatment for this neoplasm and, depending on stage consists in: local wide excision for stage I patients and local excision and lymphadenectomy for stage II. In our experience, lymphadenectomy, included in the initial treatment of all stage II patients, seemed to influence positively the prognosis. In comparing stage related recurrence and survival rates the results we obtained were better in stage II patients, where lymphadenectomy was included in the initial treatment than in stage I subjects, who received local excision alone as first treatment and lymphadenectomy as secondary treatment for nodal recurrence (overall recurrence rate 86% vs 20%, survival rate 71% vs 80% in stage I vs stage II patients). The performance of lymphadenectomy for stage I MCC could be reconsidered both for a more reliable staging of the disease and for a positive impact on recurrence and survival rates.

Original languageItalian
Title of host publicationI supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
Volume4
Edition3
Publication statusPublished - 2005

Fingerprint

Merkel Cell Carcinoma
Lymph Node Excision
Recurrence
Survival Rate
Therapeutics
Skin Neoplasms
Lymph
Skin Diseases
Lymph Nodes
Incidence
Neoplasms

Cite this

Lonardo, M. T., Marone, U., Chiofalo, M. G., Cerra, R., Mori, S., Caracò, C., ... Pezzullo, L. (2005). Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii. In I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] (3 ed., Vol. 4)

Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii. / Lonardo, M. T.; Marone, U.; Chiofalo, M. G.; Cerra, R.; Mori, S.; Caracò, C.; Misso, C.; Germano, A.; Pezzullo, L.

I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]. Vol. 4 3. ed. 2005.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lonardo, MT, Marone, U, Chiofalo, MG, Cerra, R, Mori, S, Caracò, C, Misso, C, Germano, A & Pezzullo, L 2005, Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii. in I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]. 3 edn, vol. 4.
Lonardo MT, Marone U, Chiofalo MG, Cerra R, Mori S, Caracò C et al. Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii. In I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]. 3 ed. Vol. 4. 2005
Lonardo, M. T. ; Marone, U. ; Chiofalo, M. G. ; Cerra, R. ; Mori, S. ; Caracò, C. ; Misso, C. ; Germano, A. ; Pezzullo, L. / Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii. I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]. Vol. 4 3. ed. 2005.
@inbook{479a969b04c2455a92854571eac639e5,
title = "Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii.",
abstract = "Merkel cell carcinoma (MCC) is a rare, malignant skin cancer, exhibiting neuroendocrine differentiation, with a significant incidence of locoregional lymph nodal involvement (40{\%}-73{\%}). The accepted staging system classifies MCC as: stage I, localized skin disease; stage II, regional lymph node disease; stage III, metastatic disease. The clinical differentiation of stage I and II patients is difficult and understaging is frequent. Surgery, as first approach, represents the leading treatment for this neoplasm and, depending on stage consists in: local wide excision for stage I patients and local excision and lymphadenectomy for stage II. In our experience, lymphadenectomy, included in the initial treatment of all stage II patients, seemed to influence positively the prognosis. In comparing stage related recurrence and survival rates the results we obtained were better in stage II patients, where lymphadenectomy was included in the initial treatment than in stage I subjects, who received local excision alone as first treatment and lymphadenectomy as secondary treatment for nodal recurrence (overall recurrence rate 86{\%} vs 20{\%}, survival rate 71{\%} vs 80{\%} in stage I vs stage II patients). The performance of lymphadenectomy for stage I MCC could be reconsidered both for a more reliable staging of the disease and for a positive impact on recurrence and survival rates.",
author = "Lonardo, {M. T.} and U. Marone and Chiofalo, {M. G.} and R. Cerra and S. Mori and C. Carac{\`o} and C. Misso and A. Germano and L. Pezzullo",
year = "2005",
language = "Italian",
volume = "4",
booktitle = "I supplementi di Tumori : official journal of Societ{\`a} italiana di cancerologia ... [et al.]",
edition = "3",

}

TY - CHAP

T1 - Ruolo della linfoadenectomia nel trattamento del tumore a cellule di merkel in stadio i e ii.

AU - Lonardo, M. T.

AU - Marone, U.

AU - Chiofalo, M. G.

AU - Cerra, R.

AU - Mori, S.

AU - Caracò, C.

AU - Misso, C.

AU - Germano, A.

AU - Pezzullo, L.

PY - 2005

Y1 - 2005

N2 - Merkel cell carcinoma (MCC) is a rare, malignant skin cancer, exhibiting neuroendocrine differentiation, with a significant incidence of locoregional lymph nodal involvement (40%-73%). The accepted staging system classifies MCC as: stage I, localized skin disease; stage II, regional lymph node disease; stage III, metastatic disease. The clinical differentiation of stage I and II patients is difficult and understaging is frequent. Surgery, as first approach, represents the leading treatment for this neoplasm and, depending on stage consists in: local wide excision for stage I patients and local excision and lymphadenectomy for stage II. In our experience, lymphadenectomy, included in the initial treatment of all stage II patients, seemed to influence positively the prognosis. In comparing stage related recurrence and survival rates the results we obtained were better in stage II patients, where lymphadenectomy was included in the initial treatment than in stage I subjects, who received local excision alone as first treatment and lymphadenectomy as secondary treatment for nodal recurrence (overall recurrence rate 86% vs 20%, survival rate 71% vs 80% in stage I vs stage II patients). The performance of lymphadenectomy for stage I MCC could be reconsidered both for a more reliable staging of the disease and for a positive impact on recurrence and survival rates.

AB - Merkel cell carcinoma (MCC) is a rare, malignant skin cancer, exhibiting neuroendocrine differentiation, with a significant incidence of locoregional lymph nodal involvement (40%-73%). The accepted staging system classifies MCC as: stage I, localized skin disease; stage II, regional lymph node disease; stage III, metastatic disease. The clinical differentiation of stage I and II patients is difficult and understaging is frequent. Surgery, as first approach, represents the leading treatment for this neoplasm and, depending on stage consists in: local wide excision for stage I patients and local excision and lymphadenectomy for stage II. In our experience, lymphadenectomy, included in the initial treatment of all stage II patients, seemed to influence positively the prognosis. In comparing stage related recurrence and survival rates the results we obtained were better in stage II patients, where lymphadenectomy was included in the initial treatment than in stage I subjects, who received local excision alone as first treatment and lymphadenectomy as secondary treatment for nodal recurrence (overall recurrence rate 86% vs 20%, survival rate 71% vs 80% in stage I vs stage II patients). The performance of lymphadenectomy for stage I MCC could be reconsidered both for a more reliable staging of the disease and for a positive impact on recurrence and survival rates.

UR - http://www.scopus.com/inward/record.url?scp=33644872078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644872078&partnerID=8YFLogxK

M3 - Capitolo

VL - 4

BT - I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]

ER -